CYGNOS BioTech is developing propriety antimicrobial therapeutic protected under several patents. PVX that will be commercialized for human and veterinary clinical markets. PVX is currently manufactured by chemical modification of the protein to ultimately promote biologic activity, either antiviral or antitumor (MMX).

CYGNOS PVX has already demonstrated efficacy in companion animals  (dogs, cats, horses and birds).

CYGNOS has been awarded 2 FDA investigational product INADs for PVX and MMX.

In parallel, CYGNOS is seeking funding to advance product development through FDA for the approval of the Animal INADs and a Human IND submission.

CYGNOS BioTech LLC

Org chart

Teams

Offices